A little over 100 fragile sites have now been found in the human karyotype, the majority being the common type occurring in a high proportion of persons, many of these being aphidicolin inducible. Rare 30 to 60 minutes. Cultures for fragile X induction consisted of TC199 with 5% fetal bovine serum and PHA, or Ham's FIO with PHA and 10% serum to which was added 600 mg/ml thymidine for the final 18 hours of incubation. On the repeat study of the proband, cultures were also grown in Ham's FIO plus 10% serum for three days with no blocking, and BrdU released, methotrexate blocked cultures were used to investigate replication banding patterns. Culture duration was three days in all cases.
The fragile site at 5q35 was ascertained in the methotrexate blocked cultures released with either thymidine or BrdU, and also in the TC199 cultures (table) . The highest levels of expression were obtained in methotrexate/thymidine cultures. Only 1/50 cells from the Ham's FIO cultures showed the fragile site and there was no expression in 50 cells from thymidine blocked cultures. C banding showed no evidence of differential staining in the region of the fragile site and there was no satellite attraction or silver staining associated with it. G banding suggested that the fragile locus was located within or distal to the small dark sub-band 5q35.2 (fig 1) . Replication banding was uninformative. The fragile site was clearly visible in non-banded preparations (fig 2) where it was sometimes morphologically reminiscent of the fragile X.
New fragile sites are now infrequently described and it is therefore of interest to report this observation.
The fra(5)(q35) is considered to be a folate sensitive site as its expression was extremely low in standard Ham's FIO medium, a formulation containing appreciable levels of folic acid and thymidine. However, the lack ofexpression after blocking with excess thymidine is most unusual and not typical of folate sensitive fragile sites such as the fragile X.3
The expression of the fragile locus in the methotrexate blocked, thymidine released or BrdU released cultures is compatible with folate sensitivity, as addition of the releasing agent would inhibit the fragile site only if added before its replication. Fragile site expression is considered to be S dependent for fragile X.4
The occurrence of the fragile chromosome 5 in the clinically normal brother indicates that this fragile site is coincidental to the strong history of male mental retardation in this familv and has no direct clinical consequences. Possibly it was inherited from the father who was not available for study.
